Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer

European Journal of Cancer

Volumn 43, Issue 4, 2007, Pages 799-808

  Wu, Chun Ying ^a,b,c   Wu, Ming Shiang ^d   Chen, Yi Ju ^b   Chen, Chien Jen ^e   Chen, Hsiao Ping ^b   Shun, Chia Tung ^d   Chen, Gran Hum ^b   Huang, Shih Pei ^d   Lin, Jaw Town ^d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Gastric cancer; Invasion; MMP 2; Polymorphism; TIMP 2

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENOTYPE; HUMAN; LEUKOCYTE; LYMPH FLOW; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; STOMACH CANCER; VEIN BLOOD FLOW;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 33947636758     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.10.022     Document Type: Article

References (42)

1. Ala-aho R., and Kahari V.M. Collagenases in cancer. Biochimie 87 (2005) 273-286
2. Stamenkovic I. Matrix metalloproteinases in tumour invasion and metastasis. Semin Cancer Biol 10 (2000) 415-433
3. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
4. Kahari V.M., and Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31 (1999) 34-45
5. Yu C., Pan K., Xing D., et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 62 (2002) 6430-6433
6. Murray G.I., Duncan M.E., Arbuckle E., Melvin W.T., and Fothergill J.E. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 43 (1998) 791-797
7. Miao X., Yu C., Tan W., et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 63 (2003) 3987-3990
8. Zhang J.F., Zhang Y.P., Hao F.Y., et al. DNA ploidy analysis and expression of MMP-9, TIMP-2, and E-cadherin in gastric carcinoma. World J Gastroenterol 11 (2005) 5592-5600
9. Zhou Y., Yu C., Miao X., et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25 (2004) 399-404
10. Upadhyay J., Shekarriz B., Nemeth J.A., et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 5 (1999) 4105-4110
11. Vasala K., Paakko P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 62 (2003) 952-957
12. Davidson B., Goldberg I., Gotlieb W.H., et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17 (1999) 799-808
13. Brown P.D., Bloxidge R.E., Stuart N.S., Gatter K.C., and Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumour spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85 (1993) 574-578
14. Price S.J., Greaves D.R., and Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276 (2001) 7549-7558
15. Qin H., Sun Y., and Benveniste E.N. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 274 (1999) 29130-29137
16. Pan M.R., and Hung W.C. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 277 (2002) 32775-32780
17. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
18. Howard E.W., Bullen E.C., and Banda M.J. Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem 266 (1991) 13070-13075
19. Wang Z., Juttermann R., and Soloway P.D. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 275 (2000) 26411-26415
20. De Clerck Y.A., Darville M.I., Eeckhout Y., and Rousseau G.G. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 139 (1994) 185-191
21. Hirano K., Sakamoto T., Uchida Y., et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 18 (2001) 748-752
22. Chen L.T., Lin J.T., Shyu R.Y., et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 19 (2001) 4245-4251
23. Wu M.S., Wu C.Y., Chen C.J., et al. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 104 (2003) 617-623
24. Hermanek P., and Sobin L.H. UICC: TNM classification of malignant tumours. fourth ed. (1992), Springer, Berlin
25. Hermanek P. pTNM and residual tumour classifications: problems of assessment and prognostic significance. World J Surg 19 (1995) 184-190
26. de Souza A.P., Trevilatto P.C., Scarel-Caminaga R.M., et al. Analysis of the MMP-9 (C-1562 T) and TIMP-2 (G-418C) gene promoter polymorphisms in patients with chronic periodontitis. J Clin Periodontol 32 (2005) 207-211
27. Wu M.S., Shun C.T., Wang H.P., et al. Genetic alterations in gastric cancer: relation to histological subtypes, tumour stage, and Helicobacter pylori infection. Gastroenterology 112 (1997) 1457-1465
28. Zhou Y., Yu C., Miao X., et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 26 (2005) 1117-1121
29. Park C.C., Bissell M.J., and Barcellos-Hoff M.H. The influence of the microenvironment on the malignant phenotype. Mol Med Today 6 (2000) 324-329
30. Xu E., Lai M., Lv B., et al. A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun 324 (2004) 999-1003
31. Kubben F.J., Sier C.F., Meijer M.J., et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 95 (2006) 744-751
32. Nomura H., Sato H., Seiki M., et al. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55 (1995) 3263-3266
33. Bando E., Yonemura Y., Endou Y., et al. Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncol Rep 5 (1998) 1483-1488
34. Sier C.F., Kubben F.J., Ganesh S., et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74 (1996) 413-417
35. Monig S.P., Baldus S.E., Hennecken J.K., et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 39 (2001) 597-602
36. Ji F., Chen Y.L., Jin E.Y., et al. Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 11 (2005) 3222-3226
37. Wu Z.Y., Li J.H., Zhan W.H., and He Y.L. Lymph node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma. World J Gastroenterol 12 (2006) 2941-2944
38. Jiang Y., Goldberg I.D., and Shi Y.E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21 (2002) 2245-2252
39. Hayakawa T., Yamashita K., Ohuchi E., and Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 107 (1994) 2373-2379
40. Davidson B., Goldberg I., Kopolovic J., et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 73 (1999) 372-382
41. Visscher D.W., Hoyhtya M., Ottosen S.K., et al. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumour recurrence. Int J Cancer 59 (1994) 339-344
42. Yu C., Zhou Y., Miao X., et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64 (2004) 7622-7628